Cardiovascular risk and sildenafil.

Area of Science:

• Cardiovascular Medicine
• Urology
• Pharmacology

Background:

• Erectile dysfunction (ED) is a common condition affecting many men.
• Oral agents for ED, like sildenafil, primarily work through vasodilation.
• Cardiovascular interactions are a key consideration for ED pharmacotherapy.

Purpose of the Study:

• To review the cardiovascular safety and efficacy of sildenafil in men with ED.
• To assess the risk of adverse cardiovascular events associated with sildenafil use.
• To provide guidance on patient selection and risk assessment for ED treatments.

Main Methods:

• Review of clinical trials involving men with ED, with or without cardiovascular conditions.
• Analysis of cardiovascular adverse events, including myocardial infarction and death.
• Evaluation of sildenafil's effect on systemic arterial pressure, particularly with organic nitrates.

Main Results:

• Sildenafil demonstrated efficacy in treating ED across studied populations.
• No significant increase in serious cardiovascular events, MI, or death was observed compared to placebo.
• A significant decrease in blood pressure occurs when sildenafil is combined with organic nitrates, making it contraindicated.

Conclusions:

• Sildenafil is a safe and effective oral treatment for ED in most patients.
• Physicians must counsel cardiac patients on the risks of sexual activity and evaluate cardiac status before prescribing ED treatments.
• Exercise treadmill testing may be beneficial for assessing the safety of sexual activity in patients with coronary artery disease.